Tolemy Bio has successfully raised €1.4 million to enhance its AI-driven platform aimed at revolutionizing cell biology experimentation.
The funding round, led by Norrsken Evolve and supported by several venture firms, will enable Tolemy Bio to expand its data generation and machine learning capabilities, further develop its core product, Orbit, and facilitate early deployments with academic and industry collaborators. This initiative addresses a significant challenge in biopharma: the need for reliable, reusable intelligence from complex cell biology experiments, which are critical for the development of cell therapies and therapeutic proteins.
Orbit is positioned as an AI-enabled control panel that integrates existing lab tools and data into a cohesive workspace. It combines virtual cell models with research agents to help scientists analyze how cells react to environmental changes and optimize their experimental approaches. The platform has already garnered interest from prestigious institutions like MIT and the University of Cambridge, indicating its potential impact in the field.
Founded by Alex Ward and Caelan Anderson, Tolemy Bio aims to transform the interpretation and optimization of cell biology data. With a focus on generating the experimental datasets necessary for training its virtual models, the company is also collaborating with GeminiBio to enhance cell therapy manufacturing through AI-driven media optimization. As Tolemy Bio enters a competitive landscape for AI infrastructure in biopharma, its challenge will be to demonstrate the tangible benefits of its platform in improving cell-based product development.
This funding marks a significant step for Tolemy Bio as it seeks to provide smaller biopharma companies with access to advanced AI tools, potentially leveling the playing field in drug discovery and development.